Ann: Amended Change of Director's Interest Notice, page-8

Stephen - Re: "the otherwise very positive news around covid vaccines won't help the share price".
The Main UCM product, the 1A, and all the products that are waiting in line for regulatory approval - are useful in covid treatment, but are not Covid specific devices. They are instrumental in treating medical conditions that cause around 75% of deaths in normal times.
For example the 1A is the device of choice for monitoring Sepsis and controlling its treatment - many covid patients die of sepsis. But so many people die of sepsis in normal times from a long list of other causes.

Additionally - once regulatory approvals are received and the products can be marketed - the door will be opened for a string of announcements on the application of this new technology.
Why do you think China recognized Uscom with its recent Status upgrade 4 December 2020. "Uscom China was listed second as a National High Technology Enterprise by the Chinese Office of the Leading Group of National High Technology Enterprise Identification and Management in Beijing ".
China is well aware of the future importance of this technology and that UCM has the structure to carry their range to a world market. China with typical planning and foresight would like to be a partner in making this happen. Their programs are offering incentives and support.

Why do you think the UCM director purchased his shares since the announcement - he is well aware what the next year will bring and is simply acting on the announcements (like any one can) as he does not want to be accused next year of insider trading.